Indexed by: Journal paper

First Author: Qi Yu

Correspondence Author: Xionglin Fan

Co-author: Xiaochun Wang

Journal: Frontiers in immunology

Affiliation of Author(s): 华中科技大学

Discipline: Medicine

First-Level Discipline: Basic Medicine

Document Type: J

Volume: 8

ISSN No.: 1664-3224

Key Words: IL-2+ T cells; MTOM; Mycobacterium tuberculosis; Th1-type response; adjuvant

DOI number: 10.3389/fimmu.2017.00585

Date of Publication: 2017-05-18

Impact Factor: 7.561

Teaching and Research Group: 华中科技大学基础医学院病原生物系医学微生物学

Abstract: The only licensed vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) cannot prevent the prevalence of tuberculosis (TB), which remains a major public health problem worldwide. A more effective TB vaccine than BCG is urgently needed. Subunit vaccine is a promising strategy, and suitable adjuvants will benefit the development of effective TB subunit vaccines. MTO, consisting of monophosphoryl lipid A (MPLA), trehalose-6,6'-dibehenate (TDB), and MF59, was developed as an adjuvant of TB vaccine because of its ability to evoke the Th1-type T cell responses, while it is insufficient to induce single and multifunctional IL-2+ T cells and has a limited ability to confer protection against Mycobacterium tuberculosis infection. Heat-killed Mycobacterium vaccae (Mv), which can evoke cytotoxic CD8+ and CD4+ T cell responses and has adjuvanticity, was, in this study, combined with MTO to produce a new adjuvant, called MTOM. The TB fusion protein Rv3407-PhoY2-Ag85A-Rv2626c-RpfB (WH121) was mixed with MTO, Mv, and MTOM to produce three subunit vaccines, and the protective efficacy and immune responses were compared in C57BL/6 mice. WH121/MTOM provided better protection against TB than the other two vaccines, matching the performance of BCG vaccine. MTOM showed stronger ability to increase single and multifunctional IL-2+ T cells and induce Th1-type responses than MTO or Mv. Therefore, MTOM might be a promising adjuvant that could contribute to the development of TB subunit vaccines.

Note: 9) Q. Yu, X. Wang, X. Fan. Adjuvant MTOM Mediates Mycobacterium tuberculosis Subunit Vaccine to Enhance Th1-Type T Cell Immune Responses and IL -2+ T Cells. Frontiers in Immunology, 2017, 8:585.

Links to published journals: https://pubmed.ncbi.nlm.nih.gov/28572807